|Description||Dihexa, an oligopeptide drug, is a stable bioavailable synthetic Hepatocyte growth factor (HGF) mimetic with potential to improve cognitive function in animal models of Alzheimer's disease-like mental impairment.|
|Synonyms||(2S,3S)-N-(6-amino-6-oxohexyl)-2-[[(2S)-2-(hexanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-methylpentanamide; N-hexanoic-Tyr-Ile-(6) aminohexanoic amide|
|Solubility||DMSO: ≥ 30 mg/mL|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
|Boiling Point||866.2±65.0 ℃ at 760 Torr|
Dihexa, an oligopeptide drug, is a stable bioavailable synthetic Hepatocyte growth factor (HGF) mimetic with potential to improve cognitive function in animal m...
JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.
MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively and also inhibits Ron a...
Tivantinib (ARQ-197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity. c-Met inhibitor ARQ 197 binds to the c-...
NVP-BVU972 potently inhibits MET kinase but displays low inhibition against other kinases including the most closely related kinase RON with IC50 values of more...
CEP-40783 is an orally-active, nanomolar potent and highly kinase-selective Type II inhibitor of the AXL and c-Met RTK with IC50 values of 7 nM and 12 nM, respe...
c-Met inhibitor 1
c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic can...
Crizotinib is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor.
Tepotinib, also known as EMD 1214063 and MSC2156119, is an inhibitor of MET tyrosine kinase with potential antineoplastic activity. MET tyrosine kinase inhibito...
Lys01 trihydrochloride, a water-soluble salt of Lys01, is a selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respec...
SCR-1481B1, also known as c-Met inhibitor 2, is an effective inhibitor of MET kinase so that probably has anti-tumor activity. It is also found to be an inhibit...
LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (K(i)) of 2 nM, a pharmacodynamic residence time ...
BMS-777607 is a novel prodrug of the dual Met/VEGFR-2 inhibitor.
SU11274 is a selective Met tyrosine kinase inhibitor with IC50 of 10 nM.
AMG 208 is a selective small-molecule inhibitor of the proto-oncogene c-Met with potential antineoplastic activity. C-Met encodes the hepatocyte growth factor r...
SGX523 is a novel, ATP-competitive kinase inhibitor remarkable for its exquisite selectivity for MET. SGX523 potently inhibited MET with an IC50 of 4 nmol/L an...
PF-04217903 methanesulfonate is a selective ATP-competitive c-Met inhibitor and is susceptible to oncogenic mutations (no activity to Y1230C mutant). It showed ...
This active molecular is a selective RON receptor tyrosine kinase inhibitor. The RON receptor tyrosine kinase has been reported that it usually overexpressed in...